ICIs, such as cytotoxic T lymphocyte-associated molecule-4 (CTLA-4), programmed cell death receptor-1 (PD-1), and programmed cell death ligand-1 (PD-L1), are designed to enhance the systemic antitumor immune response by interrupting coinhibitory signal pathways and eliminating tumor cells [7]. This evidence concerns the gene CD274 and neoplasm.